Recent experience includes advising:

• Magdalen College, Oxford on the creation of a 60/40 joint venture with Singaporean sovereign wealth fund GIC in relation to The Oxford Science Park, one of the first life sciences REITs in the UK.
• Having acted for Magdalen College, Oxford on the joint venture formation, we continue to act for The Oxford Science Park in relation to the asset and development management matters at the science park, including the acquisition of The Gosling Building and leaseback to Oxford Nanopore Technologies, the acquisition of The Hinshelwood Building, the lease of The Hayakawa Building and the refinancing of the science park.
• University of Cambridge on the development of a major expansion to the City of Cambridge at North West Cambridge. The completed development, potentially a 15 year project, will comprise a million sq. ft. of research and development space, affordable housing, student accommodation, (total of c.2,500 residential units) retail uses and community facilities. We have advised on the draft Area Action Plan and all areas of project strategy.
• Canary Wharf on the formation of a JV with Kadans Science Partners to develop a new 22 storey, 750,000 sq. ft. life sciences building. The development will be the first phase in the creation of a world leading centre for health and life sciences on the 3.3 hectare North Quay site next to the new Elizabeth Line station. The block, set for completion in 2026, will be the largest commercial lab space in Europe.
• Provided finance, planning and tax advice to Precis Advisory in connection with two sites in London’s Knowledge Quarter. Belgrove House is proposed as a new specialised office and laboratory building for the life-sciences sector. It will be a Discovery Hub and UK HQ/centre of excellence for MSD UK (the premier research-intensive biopharmaceutical company).
• Aviva Life & Pensions UK on the sale of 50% of their interest in the £90m science park, Chesterford Research Park, which it has sold to Uttlesford District Council, as part of a joint venture to hold and develop the research park.
• A global real estate investor on the proposed extension and refurbishment of an existing asset to create a CL2 accelerator hub for multiple life science businesses and negotiating an operating agreement with a large US-based pharmaceutical company.
• Tesco Pension Investment on the forward funding of a 100,000 sq. ft. global HQ and laboratory for Abcam at Cambridge Biomedical Campus.